UBS Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

UBS Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-29,800	Closed	-$759K	–	11171
2021 Q3	$759K	Buy	+29,800	New	+$876K	﹤0.01%	4413
2020 Q1	–	Sell	-170,800	Closed	-$13.6M	–	8599
2019 Q4	$13.6M	Buy	+170,800	New	+$10.1M	﹤0.01%	1672
2018 Q1	–	Sell	-3,600	Closed	-$142K	–	8296
2017 Q4	$142K	Buy	+3,600	New	+$134K	﹤0.01%	5148
2017 Q3	–	Sell	-5,000	Closed	-$137K	–	8106
2017 Q2	$137K	Buy	+5,000	New	+$149K	﹤0.01%	4990

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's GBT Position: Q4 2022 in Review

UBS Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 276,847 shares — an estimated $18.9M sold.

UBS Group first reported a position in GBT in Q4 2015 and held it in 26 quarters. The position peaked at $18.9M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

UBS Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
UBS Group sold 276,847 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $18.9M.
UBS Group first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 26 quarters.
UBS Group's Global Blood Therapeutics, Inc. position peaked at $18.9M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.